Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PXS-5505 with Atezolizumab and Bevacizumab in unresectable HCC
NCT05109052Phase 2Withdrawn
- Sponsor
- University of Rochester
- Start
- Sep 2022
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of amsulostat in hepatocellular carcinoma (HCC), sponsored by University of Rochester. Planned start Sep 2022; status: withdrawn.
02
Drugs
amsulostat
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05109052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05109052.